- Patent protection until 2039
- Previous human pharmacokinetic (PK) study showed
significantly better PK profile when compared to market leading
product
UPPSALA, Sweden, Jan. 27, 2021 /PRNewswire/ -- Orexo AB
(publ.), (STO: ORX) (OTCQX: ORXOY) today announces that
the company has further strengthened the intellectual property (IP)
for its flagship pharmaceutical pipeline asset OX124, a naloxone
rescue medication for the treatment of opioid overdose. The US
Patent and Trademark Office (USPTO) has issued a new patent
protecting the product until 2039.
The new patent, US 10,898,480, is the second US patent for
OX124. The first patent, US 10,653,690, was issued by the USPTO in
the summer of 2020. At that time, the first patent for Orexo's
nalmefene overdose rescue medicine, OX125, was also issued (US
10,729,687), as previously announced in the Interim Report for
Q2, 2020. Both of these patents protect the respective products
until 2039.
Based on Orexo's innovative scalable intranasal formulation
technology, OX124 is a powerful naloxone rescue medication,
designed to reverse opioid overdoses, including those from
synthetic opioids, such as fentanyl. In a previous human PK study
of OX124 (OX124-001), all formulations of OX124 were found to be
well tolerated and showed substantially higher plasma
concentrations of naloxone, sustained duration of elevated plasma
concentration, and equivalent or superior onset time when compared
to the current market leading product.1
Nikolaj Sørensen, President and CEO, said:
"Recognizing the potential of OX124 early in its development,
we have secured strong IP-rights for this novel and scalable
intranasal formulation technology. Strong patent protection for
this promising asset is critical to ensure the successful
commercialization of OX124. Too many people in the US are dying
from overdoses caused by synthetic opioids, such as fentanyl.
Covid-19 has exacerbated this crisis further, underlining the
urgent need for more powerful and faster-acting rescue medications.
We believe OX124 could reverse this trend and look forward to
reporting further progress on its development over the coming
months."
OX124 is planned to enter a pivotal bridging study in Q2 2021. A
New Drug Application (NDA) is expected to be filed with the US Food
and Drug Administration (FDA) in Q1 2022, which is based on OX124
being granted Fast Track Designation by FDA, which is expected to
be received in Q1 2021. Potential net sales for OX124, five years
post launch, is in the range of USD
70 - 110 million.
For further information, please contact:
Orexo AB (publ.)
Nikolaj Sørensen,
President and CEO
|
|
Lena Wange, IR &
Communications Director
|
Tel: +46
(0)18 780 88 00
|
|
Tel: +46
(0)18 780 88 00
|
E-mail:
ir@orexo.com
|
|
E-mail:
ir@orexo.com
|
US market for overdose rescue medications
The addressable market for OX124 is large and growing as demand
for easy to use, potent overdose reversal medication increases, not
only for emergency staff and first responders, but also for opioid
dependent patients, and as co-prescription for high-dose opioid
pain patients. According to Orexo's estimates, greater levels of
co-prescriptions and expanding access for opioid dependent patients
may increase the market size from today's USD 300-500 million to USD
1.5-2 billion.
About Orexo
Develops improved pharmaceuticals and digital therapies
addressing unmet needs within the growing space of substance use
disorders and mental health. The products are commercialized by
Orexo in the US or via partners worldwide. The main market today is
the American market for buprenorphine/naloxone products, where
Orexo commercialize its lead product ZUBSOLV® for treatment of
opioid use disorder. Total net sales for 2019 amounted to
SEK 844.8 million and the number of
employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap
(ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head
office, where research and development is also performed, is
situated in Uppsala, Sweden.
For more information about Orexo please visit,
www.orexo.com. You can also follow Orexo on Twitter,
@orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 8 am CET, on January 27,
2021.
1 https://orexo.com/investors/regulatory-press-releases/2019-01-07-positive-results-from-human-pk-study-assessing-orexo-s-new-intranasal-naloxone-formulations-for-opioid-overdose-reversal
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/orexo/r/orexo-strengthens-ip-rights-for-overdose-rescue-drug-ox124,c3274547
The following files are available for download:
https://mb.cision.com/Main/694/3274547/1363973.pdf
|
Orexo strengthens IP
rights for overdose rescue drug OX124
|